AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03508752 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Stereotactic Radiosurgery dose is based on the largest tumor size
Study NCT03750747 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulse Oximeter
Description: SpO2 will be measured using a handheld PO device (selected for this study) applying the low noise cabled sensor. For patients weighing \<10 kg, the sensor will be placed on the big toe. For patients weighing >10 kg, the sensor will be placed on an index finger. In case of failure in the first attempt, the alternate toe or index finger will be tried (second attempt). First, the sensor will be placed on toe or index finger and then the PO will be powered-on. A stable Sp02 reading will be considered to be obtained if SpO2 reading is stable by ±1 % for at least 10 seconds and the device signal strength is displayed to be adequate (green signal). Second attempt will be warranted if a stable reading is not obtaining within 1-2 minutes.
Study NCT01370824 — intervention group
Intervention type: PROCEDURE
Intervention: Punch biopsy
Description: Punch biopsy is a 10 minutes treatment at the outpatient department of dermatology. Patient will lie down on a bed, the skin will be disinfected and local anaesthesia (lidocaine 1% with epinephrine) will be given, which is briefly painful. Then a PB of 3 mm is taken from the most suspected area. In the case of continuing bleeding the wound will be sutured. A properly taken biopsy will leave no or minimal scarring, but this is not relevant since a SE will be performed afterwards. In very rare cases post-biopsy bleeding or infection occurs.
Study NCT01370824 — intervention group
Intervention type: PROCEDURE
Intervention: Surgical excision
Description: Surgical excision takes place in 30 minutes. Patient will lie down on a bed, the skin will be disinfected and local anaesthesia will be given. sBCC and nBCC will be excised with a 3 mm margin, aBCC with a 5 mm margin. Most BCC can be surgically excised, but some have to be treated with Mohs micrographic surgery (MMS). MMS ensures total BCC removal, preserving as much surrounding skin with 100% margin control. All BCCs will be excised with a 2 mm margin and examined under the microscope. This will totally take 1.5-2.0 hours. If tumour is still present, another tissue layer with 2 mm margin will be excised. It usually takes removal of 1-3 tissue layers to complete MMS.~After both treatments, wounds will be sutured and removed after 1-2 weeks, depending on the localisation. Within the first two weeks posttreatment, patients have to avoid physical heavy movements and keep the suture dry. Possible complications: scarring, continuous or subsequent bleeding, infection and dehiscent wounds.
Study NCT01103102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iocide Oral Rinse
Description: Oral Rinse; dosages vary by treatment group; once to twice daily use (depending on treatment group); 12 weeks duration
Study NCT01103102 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02326922 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Metraplant-E levonorgestrel-releasing intrauterine device
Description: Metraplant-E insertion and follow up for 6 months
Study NCT01060605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rapamycin
Description: Pre-transplant rapamycin is administered for at least four weeks prior to the first islet infusion at the dose of 0.1 mg/kg (target trough levels: 8-10 ng/mL).
Study NCT03912818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT03912818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT03912818 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cystectomy
Description: Undergo cystectomy
Study NCT03912818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV
Study NCT03912818 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV
Study NCT04358068 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Hydroxychloroquine
Description: Administered orally
Study NCT04358068 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Azithromycin
Description: Administered orally
Study NCT01936298 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A-ROM Continuous Passive Rehabilitation
Description: Half an hour of treatment during the morning with the sequential program (each finger is mobilized individually) and half an hour of treatment during the afternoon with the synchronous program (II-III-IV-V finger are mobilized simultaneously, the thumb individually).
Study NCT01936298 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: P-ROM Continuous Passive Rehabilitation
Description: Half an hour of treatment during the morning with the sequential program (each finger is mobilized individually) and half an hour of treatment during the afternoon with the synchronous program (II-III-IV-V finger are mobilized simultaneously, the thumb individually).
Study NCT00819013 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A Vaccine: ACAM FLU-A
Description: 0.5 mL ACAM-FLU-A low dose + Adjuvant 1, Intramuscular
Study NCT00819013 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A Vaccine: ACAM FLU-A
Description: 0.5 mL ACAM-FLU-A low dose + Adjuvant 2, Intramuscular
Study NCT00819013 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A Vaccine: ACAM FLU-A
Description: 0.5 mL ACAM FLU-A low dose, Intramuscular
Study NCT00819013 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline placebo
Description: 0.5 mL, Intramuscular
Study NCT00979745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afamelanotide
Description: One 16mg subcutaneous implant every 2 months for 9 months.
Study NCT00979745 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One 16mg subcutaneous implant every 2 months for 9 months.
Study NCT03912818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV
Study NCT02870751 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TW11681 or TW10722
Study NCT04778449 — intervention group
Intervention type: OTHER
Intervention: Medical Chart Review
Description: Medical charts are reviewed
Study NCT04778449 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study NCT01678898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRX-102
Study NCT03489837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levotuss
Description: oral taken
Study NCT03489837 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levotuss
Description: oral taken
Study NCT00352391 — intervention group
Intervention type: OTHER
Intervention: Assessments
Description: At Months 6, 12, 18, 24, 30, and 36, complete medical history will be recorded, and a physical exam will be performed by either a doctor or a nurse. At each of these visits, blood will be drawn for routine tests (about 3 teaspoons) and for research purposes (about 4 teaspoons). Also, a chest x-ray and a chest CT will be done at these visits.
Study NCT03600519 — intervention group
Intervention type: DEVICE
Intervention: NOTAL OCT V2.5
Description: AMD Patients
Study NCT02897999 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QBKPN
Description: QBKPN Site Specific Immunomodulators
Study NCT02897999 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT03912818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV
Study NCT03912818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: Given IV
Study NCT04724577 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: carbon ion radiotherapy
Description: dose escalation radiotherapy with five levels of dose from 54GyE/12Fx to 58.8GyE/12Fx
Study NCT02039973 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Task-sharing approach to group therapy
Description: Participants will also identify, select and clarify common concerns/problems; provide orientation to steps in problem-solving; break down identified problems into manageable pieces; choose pieces of problem to address in facilitated discussion of problem solving for implementing solutions; support the sharing of feedback of strategies used in problem-solving and maintaining pleasurable activities.~Additionally, the intervention to aim to effect behavior by: explaining the links between problems, negative thoughts, choices made on a day-to-day basis, behaviors, and mood (symptoms of depression); facilitate sharing of practical skills to tackle problems, to change mood-related thoughts, choices and/or behaviors; offer and provide feedback on homework assignments to encourage practice of skills; and help participants attribute reported improvements to the use of new skills during feedback sessions.
Study NCT02039973 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced standard of care
Study NCT02209805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIRB 796 BS, low dose
Study NCT02209805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIRB 796 BS, high dose
Study NCT02209805 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02768441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamphetamine
Description: Participants will receive 60 mg Dexamphetamine SR daily for 5 consecutive days
Study NCT02346110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine-adrenaline
Description: 50 mg bupivacaine and 50 μg adrenalin
Study NCT02346110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine-adrenaline
Description: 50 mg bupivacaine and 50 μg adrenalin
Study NCT02346110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 4 mg
Study NCT02346110 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sodium chloride
Description: 1 mL of sodium chloride solution as placebo
Study NCT01844206 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epidural Morphine
Description: Patients will be given 3mg epidural morphine, 24 hours after the initial dose.
Study NCT01844206 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Epidural Saline
Description: Patients will be given epidural saline 6ml, 24 hours after receiving epidural morphine 3 mg.
Study NCT04319081 — intervention group
Intervention type: DRUG
Intervention: PCSK9 inhibitor
Description: Patients are included after PCSK9 inhibitors prescription , at the first dispensation
Study NCT03170466 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Primary Palliative Care
Description: The intervention will span 4 domains: symptom management (e.g., dyspnea), psychosocial support (e.g., anxiety), advance care planning (e.g., understanding prognosis and electing a proxy) and care coordination (e.g., communication across providers).
Study NCT03179293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: propofol 1 mg/kg IV bolus will be given to the patient with a further 2 mg/kg administered manually over the next 3 min prior to the patient leaving the OR
Study NCT03179293 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline will be administered manually over the next 3 min prior to the patient leaving the OR
Study NCT02919267 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Double lumen tube
Description: Either gaseous volume quantification or intrapulmonary pressure measurements will be done in patients randomized in the L-DLT group.
Study NCT02919267 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Bronchial blocker
Description: Either gaseous volume quantification or intrapulmonary pressure measurements will be done in patients randomized in the BB group.
Study NCT03635385 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Apheresis technics
Description: Blood draw will be performed for anti bodies dosages
Study NCT01668953 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma (PRP) Injection
Description: 1. The subcutaneous soft tissues of the lateral elbow will be infiltrated with 1% lidocaine for local anesthetic.~2. A 22-gauge needle will then be placed into the tendon followed by 15-25 gentle strokes of dry needling in which the needle pierces the tendon at multiple sites.~3. For the PRP preparation, the Arthrex ACP system will be used. This is a closed, double syringe system which uses 16 mL of whole blood drawn from the patient's contralateral arm, using a 19G butterfly needle. The blood is centrifuged at 1500 rpm for 5 minutes and extracts 4-7 ml of PRP. No anticoagulant will be used.~4. Fenestration of the tendon will continue as 3mL of PRP is injected into the common extensor tendon.~5. The remaining PRP will be sent for analysis of platelet, WBC, and RBC concentrations.
Study NCT01668953 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whole Blood Injection
Description: 1. The subcutaneous soft tissues of the lateral elbow will be infiltrated with 1% lidocaine for local anesthetic.~2. A 22-gauge needle will then be placed into the tendon followed by 15-25 gentle strokes of dry needling in which the needle pierces the tendon at multiple sites.~3. 6mL of autologous whole blood will be drawn from the patient's contralateral arm, using a 19G butterfly needle.~4. Fenestration of the tendon will continue as 3mL of whole blood biologic agent is injected into the common extensor tendon.~5. The remaining 3mL will be sent for analysis of platelet, WBC, and RBC concentrations.
Study NCT01668953 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dry Needle Fenestration
Description: 1. The subcutaneous soft tissues of the lateral elbow will be infiltrated with 1% lidocaine for local anesthetic.~2. 3mL of autologous whole blood will be drawn from the patient's contralateral arm, using a 19G butterfly needle, and discarded.~3. A 22-gauge needle will then be placed into the tendon.~4. 15-25 strokes or as many strokes required until tendon is softened of dry needling will be performed in which the needle pierces the tendon at multiple sites. No blood will be injected into the tendon.
Study NCT01668953 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham Injection
Description: 1. The subcutaneous soft tissues of the lateral elbow will be infiltrated with 1% lidocaine (no epinephrine) for local anesthetic.~2. 3mL of autologous whole blood will be drawn from the patient's contralateral arm, using a 19G butterfly needle, and discarded.~3. The superficial subcutaneous soft tissues will be re-entered however, the tendon itself will not be entered and nothing will be injected.
Study NCT02160847 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DRIVE Program
Description: The DRIVE program (Developing Relationships that Include Values of Eating and Exercise) is a home-based parent training program, which involves 15 sessions focusing on parent-child interactions, health and nutrition, and physical activity
Study NCT00688311 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Synbiotic 2000
Description: A preparation consisting of 4 species of probiotic bacteria (10\^10 each) combined with 4 types of dietary fiber (2.5g each).
Study NCT00688311 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02719353 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: comfilcon A Extended Range test lens
Description: contact lens
Study NCT02719353 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: comfilcon A Extended Range test lens
Description: contact lens
Study NCT02719353 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: comfilcon A control lens
Description: contact lens
Study NCT02719353 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: comfilcon A control lens
Description: contact lens
Study NCT03340233 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI (cardiac) off-label use gadolinium contrast (IND exempt)
Description: Clinical MRI
Study NCT03340233 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI (cardiac)
Description: MRI without contrast
Study NCT02947256 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard laparoscopic cholecystectomy
Description: which included the classic dissection of Calot's triangle to achieve the CVS, with separate clipping and division of cystic duct and artery
Study NCT02947256 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RI approach
Description: which included separation of the lower third of GB from its bed down to its pedicle (artery and duct) with mass ligation of both.
Study NCT02134899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Change from a calcineurin inhibitors-based immunosuppression to an everolimus-based immunosuppression
Study NCT02134899 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcineurin inhibitors maintenance
Description: Usual treatment
Study NCT04501783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: TL-FVP-t will be administered orally
Study NCT04501783 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care (SOC)
Description: SOC will include standard etiotropic therapy (umifenovir + intranasal recombinant interferon alpha, or hydroxychloroquine, or chloroquine) according to MoH of Russian Federation recomendations for COVID-19
Study NCT04501783 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard concomitant therapy
Description: Standard of care according to MoH of Russian Federation recomendation for COVID-19
Study NCT04501783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard concomitant therapy
Description: Standard of care according to MoH of Russian Federation recomendation for COVID-19
Study NCT03966937 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Hot Pack will be applied on Quadriceps muscles before session for general relaxation for 7-10 minutes. Stretching of quadriceps femoris muscle with 4 repetitions and 15 second hold per session will be performed. Strengthening exercises of 3 sets of 10 RM with progressive loading per session will be performed.~Then after wearing gloves and appropriate personal protective measures, a thin filiform needle will be inserted which will penetrate into the skin and stimulate underlying myofascial trigger points.
Study NCT03966937 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Hot Pack will be applied on Quadriceps muscles before session for general relaxation for 7-10 minutes. Stretching of quadriceps femoris muscle with 4 repetitions and 15 second hold per session will be performed. Strengthening exercises of 3 sets of 10 RM with progressive loading per session will be performed.
Study NCT03285503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole IM Depot
Description: administration of Aripiprazole IM Depot formulation at doses of 400 mg for 5 times in patients with schizophrenia.
Study NCT02763397 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NBM-DBS
Description: DBS which has already been implanted aiming initially to stimulate the GPi will be reprogrammed in order to stimulate more distal structure, the NBM.
Study NCT02763397 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: DBS
Description: DBS will be switched off
Study NCT03524352 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fecal microbiota
Description: fecal microbiota in suspension
Study NCT03524352 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sterile saline
Study NCT04972370 — intervention group
Intervention type: OTHER
Intervention: Patients with Unilateral Cleft Lip with or without Cleft Palate
Description: 2 dimensional Photographs of patients with unilateral cleft lip with or without cleft palate
Study NCT03785613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test Product T1: Buprenorphine patch (9 mg)
Description: Buprenorphine transdermal patch formulation, containing 9 milligrams buprenorphine in an active surface area of 25 square centimeters.
Study NCT03785613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test Product T2: Buprenorphine patch (3.8 mg)
Description: Buprenorphine transdermal patch formulation, containing 3.8 milligrams buprenorphine in an active surface area of 10 square centimeters.
Study NCT03785613 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference Product R: Transtec patch (20 mg)
Description: Transtec (Registered Trademark) transdermal patch containing 20 milligrams buprenorphine in an active surface area of 25 square centimeters, release rate 35 micrograms per hour.
Study NCT03785613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo patch to T1
Description: Placebo patch to T1.
Study NCT03785613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo patch to T2
Description: Placebo patch to T2.
Study NCT03785613 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Matching placebo patch to R
Description: Placebo patch to R.